Smart Drug Development And Design To Be Discussed At Symposium Hosted By Catalent Applied Drug Delivery Institute And Boehringer Ingelheim

SOMERSET, N.J. – January 29, 2019 — The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Smart Drug Development and Design” on Wednesday, Feb. 13, 2019 at Boehringer Ingelheim’s campus in Danbury, Connecticut.

The event will be chaired by Cornell Stamoran, Ph.D., Co-Chair of the Catalent Applied Drug Delivery Institute and will feature scientific experts from leading pharmaceutical companies, including Keith Horspool, Ph.D., Vice President, Pharmaceutics, Boehringer Ingelheim. The event will explore the key considerations for transitioning a molecule from discovery to Phase 1 readiness, including API and formulation development, pharmacokinetics, quality and CMC requirements, as well as the incorporation of patient-focused design concepts. The agenda is highly interactive with activities designed for the audience to work in teams to apply the principles from the presentations, and with ample time for networking.

“Despite advances in science and technology, the pharmaceutical industry faces high attrition rates. The experts at these workshops will share strategies that can be employed during preclinical and early clinical stages of drug development that can potentially improve chances of success,” commented Dr. Stamoran.

Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies to improve patient outcomes. 

Registration and full details of the agenda can be found here.

Media Contacts:

Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0)161 728 5880


The Catalent Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
For more details on the Catalent Institute, visit and follow the Catalent Institute on Twitter: @DrugDeliveryIns


Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™